Clinical Features and Outcomes of Pneumonitis related Anti-Programmed Death-1 therapy in Non-Small Cell Lung Cancer Patients

Clinical Features and Outcomes of Pneumonitis related Anti-Programmed Death-1 therapy in Non-Small Cell Lung Cancer Patients: Retrospective multicenter observational study - Pneumonitis related Anti-Programmed Death-1 therapy in Non-Small Cell Lung Cancer Patients: Retrospective multicenter observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039149

Enrollment

580

Registered

2020-02-01

Start date

2018-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received nivolumab or pembrolizumab between January 2016 and August 2018

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
The incidence of anti PD-1 therapy related pneumonitis	—

Secondary

Measure	Time frame
frequency of treatment resistance and flare of anti PD-1 therapy related pneumonitis	—

Countries

Japan

Contacts

Public ContactTakafumi Koyauchi

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

t.koya@hama-med.ac.jp053-435-2111

Outcome results